VATS thymectomy for myasthenia gravis

2000 ◽  
Vol 9 (3) ◽  
pp. A185
Author(s):  
Gavin M. Wright ◽  
Stephen Barnett ◽  
C.Peter Clarke
2017 ◽  
Vol 2 ◽  
pp. 12-12 ◽  
Author(s):  
Bianca Bromberger ◽  
Joshua Sonett

2007 ◽  
Vol 16 ◽  
pp. S18-S19
Author(s):  
C. Keating ◽  
Y. Kong ◽  
V. Tay ◽  
S. Knight ◽  
C.P. Clarke ◽  
...  

2011 ◽  
Vol 27 (6) ◽  
pp. 595-598 ◽  
Author(s):  
Ketan Parikh ◽  
Amrish Vaidya ◽  
Rajesh Jain

ASVIDE ◽  
2017 ◽  
Vol 4 ◽  
pp. 437-437
Author(s):  
Maurizio Infante ◽  
Cristiano Benato ◽  
Riccardo Giovannetti ◽  
Cinzia Bonadiman ◽  
Barbara Canneto ◽  
...  

2001 ◽  
Vol 8 (6) ◽  
pp. 335-339
Author(s):  
Anthony P.C. Yim

2019 ◽  
Vol 6 (6) ◽  
pp. 2159
Author(s):  
Raj N. Gajbhiye ◽  
Hemant Bhanarkar ◽  
Vikrant V. Akulwar ◽  
Bhupesh Tirpude ◽  
Niketan Jambhulkar ◽  
...  

Background: Myasthenia gravis (MG) is an autoimmune disease affecting acetylcholine postsynaptic receptor of voluntary muscles. Thymectomy is a mainstay in the treatment for myasthenia gravis with or without thymoma. For many years transsternal and transcervical thymectomy had been the most common approaches used, video assisted thoracoscopic thymectomy is still not accepted as approach of choice. We intend to study the role of Video assisted thoracoscopic thymectomy for myasthenia gravis in central Indian population.Methods: Study was conducted in single tertiary care institute from January 2015 to November 2018. It is a prospective study. Aims of the study were to evaluate the safety and feasibility of video assisted thoracoscopic thymectomy for patients of myasthenia gravis. All patients of myasthenia gravis who underwent underwent video assisted thoracoscopic thymectomy (VATS) were included in the study. Intraoperative and postoperative details were studied to assess the safety and feasibility of VATS for treatment of myasthenia gravis.Results: 16 patients including 7 men and 9 women with the mean age of 35.5 years were investigated. All patients had myasthenia gravis, 12 pts had thymoma while remaining 4 pts had normal thymus. Mean operating time was 104 mins, Mean intraoperative blood loss was 45 ml (range 20 to 60 ml). There was no major intraoperative or postoperative complication or mortality. Mean ICU stay and hospital stay was 33 hrs and 4.25 days respectively.Conclusions: VATS thymectomy is safe and effective approach for the treatment of MG with or without thymoma. MG treated by VATS resulted in comparable neurological outcomes to those associated with the transsternal approach.


2019 ◽  
Author(s):  
Shoujun Fei ◽  
Hengfu Xia ◽  
Xiaowei Chen ◽  
Dazhi Pang ◽  
Xuebing Xu

Abstract Background: Using a minimum dose of neuromuscular blockade (NMB) to achieve intubation condition is one of the goals in anaesthesia management of patients with myasthenia gravis (MG) for thoracoscopic (VATS) thymectomy. However, tracheal intubation with double lumen tube (DLT) could be challenging if intubation condition is not optimal. This double-blind randomised controlled study was designed to investigate whether magnesium sulfate would reduce the rocuronium dose needed for DLT intubation and improve the DLT placement condition for patients with MG who were scheduled for video-assisted thoracoscopic (VATS) thymectomy. Methods: Recruited patients were randomly assigned to receive magnesium sulfate 60mg.kg -1 or normal saline (control) prior to the administration of NMB. Titrating dose of rocuronium was administered to achieve train of four (TOF) ratio less than 10% before DLT intubation. The primary outcome was the rocuronium dose required to achieve TOF ratio less than 10%. The secondary outcome was intubation condition for DLT placement. Results: Twenty-three patients had received magnesium sulfate and 22 patients had received normal saline before rocuronium administration. The required rocuronium dose[mean (standard deviation)] were 0.10 (0.05) mg.kg -1 and 0.28(0.17) mg.kg -1 in patients who had magnesium sulfate and normal saline respectively( P <0.0001). With a similar depth of neuromuscular blockade and depth of anaesthesia, 100% of patients in the magnesium sulfate group and 72.7% of patients in the control group showed excellent intubation condition ( P = 0.027) respectively. The patients in both groups had similar emergence characteristics. Conclusions: Magnesium sulfate is associated with a decrease in rocuronium requirement for an optimal DLT intubation condition in patients with MG for VATS thymectomy. Trial registration: Clinical Trial Registry of China (http://www.chictr.org.cn ) identifier:ChiCTR-1800017696, retrospectively registered on August 10, 2018. Key words : Magnesium sulfate; double lumen tube; myasthenia gravis; intubation; rocuronium


Sign in / Sign up

Export Citation Format

Share Document